English  丨  中文
English  丨  中文
About Us

The founders and executives of Sirnaomics, Inc. bring valuable expertise from the biopharmaceutical industry as well as finance and business management.

Patrick Y. Lu, Ph.D.


President & CEO

Chairman of Board, Suzhou Sirnaomics Pharmaceuticals Co. Ltd.

David M. Evans, Ph.D, 

Chief Scientific Officer


Michael Molyneaux, MD, MBA

Chief Medical Officer

George Ji, MBA



Senior Vice President

Marc M. Lemaître, Ph.D

Chief Operation Officer


Dmitry Samarsky, Ph.D. 

Chief Technology Officer


Alan Y. Lu, Ph.D, MBA, 

Executive Vice President,

Product Development

Steven Z. Long, Ph.D. 

Sr Vice President

John Xu, MD 

Vice President

GM, Suzhou Sirnaomics Biopharmaceuticals Co. Ltd.

Steven Long, Ph.D, Senior Vice President & China Clinical Head
Steven has 30 years of pharmaceutical experience throughout US and China. He has cofounded several biotechnology businesses in the United States, including AnGes, Inc., Personal Diagnostix (PDx), and Health Interactive Inc.  Dr. Long served as the Unit Head of Molecular Core and Clinical Support for Gene and Cell Therapy at Novartis Pharmaceuticals, the founding Vice President of AnGes Inc., and the Founder and President of Personal Diagnostix, Inc. During his 8 ½ years tenure at AnGes, the company successfully filed its first INDs in the US and went IPO to raise $180 million in open markets and received $179 million from Daichi Pharmaceuticals for the co-development of hepatocyte growth factor (HGF) for the treatment of peripheral artery disease (PAD) and ischemic heart disease (IHD).  Dr. Long is a veteran in the highly regulated pharmaceutical / biotech industry and had worked with the FDA in several diverse therapeutic areas including cancer, cardiovascular disease, infectious disease and gene and cell therapy. He had played major roles in more than 20 clinical trials from phases I to III covering therapeutic areas of gene and cell therapy, cancer, cardiovascular disease, organ and bone marrow transplantation, AIDS, dermatitis, and wound healing in 19 countries including Japan, Europe and North America. Dr. Long received his B.Sc. in Biology (Genetics major) from Fudan University in Shanghai in 1982 and his Ph.D. in Genetics from Leeds University in England in 1987, followed by postdoctoral fellowships at University of Pennsylvania and Hoffmann-La Roche Inc.

Alan Y. Lu, Ph.D, MBA, Executive Vice President for Product Development. Dr. Lu has significant experience in both academic and industrial settings focused on vaccine and therapeutic development. Prior to joining Sirnaomics, he served as the VP for Research and Business Development, Synaptic Research and as a Research Associate with a faculty appointment at the Department of Neurology, Johns Hopkins University School of Medicine. Dr. Lu received his Ph.D. from Univ. of Illinois (UIUC), Urbana, Illinois and postdoctoral training from NIH and UIUC. Dr. Lu also received his MBA from The Johns Hopkins Carey Business School.